Shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) have received a consensus recommendation of “Hold” from analysts. According to Marketbeat.com, seven research firms currently covering the stock have issued ratings, with four analysts endorsing a hold position and three advocating for a buy recommendation. The average one-year price target among these analysts stands at $80.60.
Several brokerages have recently updated their assessments of Prestige Consumer Healthcare. On October 21, Oppenheimer lowered its price target for the company from $82.00 to $72.00 while maintaining an “outperform” rating. Following this, Canaccord Genuity Group revised its target price from $100.00 to $88.00 on November 7, also granting a “buy” rating. In a notable shift, Zacks Research upgraded Prestige from a “strong sell” to a “hold” rating on November 10.
In addition, Jefferies Financial Group reduced its price target from $70.00 to $66.00 with a “hold” recommendation on January 30, while Weiss Ratings reaffirmed a “hold (c)” rating on January 22.
Institutional investors have also been active, adjusting their stakes in Prestige Consumer Healthcare. AQR Capital Management LLC increased its position by 11.9%, now holding 30,056 shares valued at approximately $2.56 million. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings by 4.6%, acquiring an additional 1,289 shares.
Furthermore, Goldman Sachs Group Inc. boosted its stake by 28.4%, now owning 546,672 shares valued at around $47 million after purchasing an additional 120,965 shares. Jane Street Group LLC significantly increased its stake by 204.0%, owning 104,802 shares valued at approximately $9 million. Lastly, Geneos Wealth Management Inc. raised its holdings by 92.8%, acquiring 269 shares in the last quarter. Notably, institutional investors currently hold 99.95% of the company’s stock.
On the trading front, shares of Prestige Consumer Healthcare opened at $66.48 on Friday. The company boasts a market capitalization of $3.20 billion and a price-to-earnings ratio of 17.59. Its performance metrics include a PEG ratio of 2.06 and a beta of 0.43. The 50-day moving average price is $63.19, while the 200-day moving average stands at $64.06. Over the past year, the company’s stock has fluctuated between a low of $57.25 and a high of $90.04.
Prestige Consumer Healthcare recently reported its quarterly earnings on February 5, revealing earnings per share (EPS) of $1.14. This figure fell short of analysts’ expectations, which were set at $1.16, marking a $0.02 miss. The company reported a revenue of $283.44 million, also below the estimated $286.93 million. Year-over-year, the revenue declined by 2.4%, compared to an EPS of $1.22 in the same quarter last year. Looking ahead, Prestige Consumer Healthcare has set its fiscal year 2026 guidance at an EPS range of 4.540-4.540, with analysts predicting an EPS of 4.5 for the current year.
In summary, as Prestige Consumer Healthcare navigates these financial assessments and market fluctuations, its position remains a focal point for investors and analysts alike. The company continues to be a key player in the over-the-counter healthcare sector, developing a range of products that address various consumer health needs, including pain relief and women’s health.
